A case report of peritoneal dialysis–associated peritonitis caused by Mycobacterium mageritense

Non-tuberculous mycobacteria can result in peritoneal dialysis (PD)-associated peritonitis and PD catheter-related infections, including tunnel and exit site infection. We report the case of a 78-year-old male patient undergoing PD for end-stage renal failure due to diabetic nephropathy, with a medical history that includes PD catheter-related infections. He developed <i>Mycobacgerium mageritense</i> peritonitis secondary to a PD catheter-related infection. <i>M. mageritense</i> grew on blood agar, and its identification was confirmed using matrix-assisted laser desorption ionization-time of flight/mass spectrometer (MALDI-TOF/MS) and 16S rRNA sequencing. Based on susceptibility testing, treatment was initiated with trimethoprim/sulfamethoxazole (TMP/SMX) (80 mg/400 mg) 5 mg/kg every 24 hours in combination with minocycline 100 mg every 12 hours, which was subsequently changed to TMP/SMX plus faropenem 200 mg every 8 hours due to nausea caused by minocycline. However, the antimicrobial therapy proved to be ineffective, and the patient subsequently developed complicated PD-associated peritonitis, leading to the removal of the PD catheter. We switched to TMP/SMX, imipenem/cilastatin 500 mg every 12 hours, and used linezolid 600 mg every 12 hours, which was later replaced with amikacin, guided by therapeutic drug monitoring. Subsequent complications related to antimicrobial therapy included nausea caused by linezolid and hearing impairment due to amikacin. We treated the patient with TMP/SMX and sitafloxacin 100 mg every 24 hours, which was well-tolerated. The patient was treated for 18 months without a relapse. Our findings underscore the importance of suspecting non-tuberculous mycobacteria in PD catheter-related infection and considering the early inclusion of acid-fast bacillus culture. Given the diagnostic challenges and the complexity of managing multi-drug antimicrobial therapy in patients with renal dysfunction, we recommend early catheter removal.

Authors

Institutions

Publication Details

Journal
IJID Regions
Published
2025-05-08
DOI
https://doi.org/10.1016/j.ijregi.2025.100659
Primary Topic
Mycobacterium research and diagnosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A case report of peritoneal dialysis–associated peritonitis caused by Mycobacterium mageritense

Nobuyoshi Mori, Masaaki Nakayama, Nozomi Kadota, Kazuhiro Ishikawa
IJID Regions
Mycobacterium research and diagnosis
article

A case report of peritoneal dialysis–associated peritonitis caused by Mycobacterium mageritense

Nobuyoshi Mori, Masaaki Nakayama, Nozomi Kadota, Kazuhiro Ishikawa
article en

Abstract

Non-tuberculous mycobacteria can result in peritoneal dialysis (PD)-associated peritonitis and PD catheter-related infections, including tunnel and exit site infection. We report the case of a 78-year-old male patient undergoing PD for end-stage renal failure due to diabetic nephropathy, with a medical history that includes PD catheter-related infections. He developed <i>Mycobacgerium mageritense</i> peritonitis secondary to a PD catheter-related infection. <i>M. mageritense</i> grew on blood agar, and its identification was confirmed using matrix-assisted laser desorption ionization-time of flight/mass spectrometer (MALDI-TOF/MS) and 16S rRNA sequencing. Based on susceptibility testing, treatment was initiated with trimethoprim/sulfamethoxazole (TMP/SMX) (80 mg/400 mg) 5 mg/kg every 24 hours in combination with minocycline 100 mg every 12 hours, which was subsequently changed to TMP/SMX plus faropenem 200 mg every 8 hours due to nausea caused by minocycline. However, the antimicrobial therapy proved to be ineffective, and the patient subsequently developed complicated PD-associated peritonitis, leading to the removal of the PD catheter. We switched to TMP/SMX, imipenem/cilastatin 500 mg every 12 hours, and used linezolid 600 mg every 12 hours, which was later replaced with amikacin, guided by therapeutic drug monitoring. Subsequent complications related to antimicrobial therapy included nausea caused by linezolid and hearing impairment due to amikacin. We treated the patient with TMP/SMX and sitafloxacin 100 mg every 24 hours, which was well-tolerated. The patient was treated for 18 months without a relapse. Our findings underscore the importance of suspecting non-tuberculous mycobacteria in PD catheter-related infection and considering the early inclusion of acid-fast bacillus culture. Given the diagnostic challenges and the complexity of managing multi-drug antimicrobial therapy in patients with renal dysfunction, we recommend early catheter removal.

IJID RegionsVol. 15
St. Luke's International Hospital (JP)
Good health and well-being
Openalex Percentile: Top 85%
Mycobacterium research and diagnosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.